Physician profile
Mark Tan
NPI 1083770580
$20,566.84
in general payments reported to CMS, 2019-2025
35 companies · $3,078 in 2025
The $3,078 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,323 · 2020: $2,026 · 2021: $2,462 · 2022: $2,930 · 2023: $3,733 · 2024: $3,014 · 2025: $3,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,448 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,448.48 |
| Education | $376.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,419.23 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $2,984.89 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Abbvie INC. | $2,721.73 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,928.80 | 2019-2025 | |
| Pfizer INC. | $1,659.40 | 2019-2025 | |
| Lilly USA, LLC | $1,504.45 | 2019-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $1,461.58 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $856.80 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.41 | 2019-2025 | Ofev, Cyltezo |
| Radius Health, INC. | $544.33 | 2020-2024 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $526.06 | 2021-2025 | Saphnelo, Evusheld |
| Genentech USA, INC. | $522.85 | 2019-2025 | Actemra, Rituxan |
| Hikma Pharmaceuticals USA | $218.20 | 2019-2023 | Mitigare |
| Pacira Therapeutics, INC. | $176.72 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $170.32 | 2023 | Idacio |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $162.24 | 2019 | |
| Alexion Pharmaceuticals, INC. | $147.16 | 2022-2025 | Strensiq |
| Mallinckrodt Enterprises LLC | $133.28 | 2019 | |
| Genzyme Corporation | $112.35 | 2019-2023 | |
| Ucb, INC. | $85.54 | 2021-2025 | Bimzelx |
| Zyla Life Sciences, INC. | $77.61 | 2019 | |
| Lundbeck LLC | $74.73 | 2020-2021 | |
| Bioventus LLC | $69.73 | 2023-2024 | Supartz Fx Sodium Hyaluronate, Supartz Fx Sodium Hyaluronate |
| Argenx US, INC. | $52.70 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Ferring Pharmaceuticals INC. | $51.92 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $39.89 | 2025 | Lupkynis |
| Depuy Synthes Sales INC. | $38.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $35.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.34 | 2019-2020 | |
| Sobi, INC | $25.02 | 2019 | |
| Biogen, INC. | $19.84 | 2025 | Spinraza |
| Medexus Pharma, INC. | $18.65 | 2019 | |
| Assertio Therapeutics, INC. | $15.88 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.74 | 2021 | |
| Avion Pharmaceuticals | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.